Onternabez: Difference between revisions
No edit summary |
Slothwizard (talk | contribs) No edit summary Tags: Visual edit Mobile edit Mobile web edit |
||
(243 intermediate revisions by 52 users not shown) | |||
Line 1: | Line 1: | ||
{{short description|Cannabidiol-derivative drug}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
|||
| Watchedfields = changed |
| Watchedfields = changed |
||
| class = [[CB2 receptor|CB<sub>2</sub> receptor agonist]] |
|||
| verifiedrevid = 426291380 |
| verifiedrevid = 426291380 |
||
| IUPAC_name = [( |
| IUPAC_name = [(1''S'',2''S'',5''S'')-2-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol |
||
| image = |
| image = Onternabez.svg |
||
| |
| caption = |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
⚫ | |||
| pregnancy_US = <!-- A / B / C / D / X --> |
|||
⚫ | |||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
||
| legal_CA = |
| legal_CA = Schedule II |
||
| legal_UK = |
| legal_UK = Class B |
||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
| legal_US = Unscheduled <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> <BR> |
||
| legal_US_comment = |
|||
| legal_status = |
| legal_status = Florida: Schedule I |
||
| routes_of_administration = |
| routes_of_administration = <!--Pharmacokinetic data--> |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Pharmacokinetic data--> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Identifiers--> |
|||
⚫ | |||
| CAS_number = 256934-39-1 |
| CAS_number = 256934-39-1 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| ATC_prefix = |
|||
| UNII = 8I5L034D55 |
|||
⚫ | |||
| |
| ATC_prefix = None |
||
⚫ | |||
| PubChem = 11553430 |
|||
| ChEBI = 146244 |
|||
| synonyms = HU-308, HU308, PPP-003, ARDS-003 |
|||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
| KEGG = D12305 |
|||
| ChemSpiderID = 8020425 |
|||
<!--Chemical data--> |
<!--Chemical data-->| C = 27 |
||
| C=27 | H=43 | O=2 |
|||
| H = 42 |
|||
| molecular_weight = 414.621 g/mol |
|||
| O = 3 |
|||
| smiles = CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC) |
| smiles = CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)[C@H]2C=C([C@@H]3C[C@H]2C3(C)C)CO)OC |
||
| StdInChI = 1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20-,21-,22+/m0/s1 |
|||
| StdInChIKey = CFMRIVODIXTERW-FDFHNCONSA-N |
|||
}} |
}} |
||
'''HU-308''' is a |
'''Onternabez''' (also known as '''HU-308''', '''HU308''', '''PPP-003''', and '''ARDS-003''') is a [[Synthetic cannabinoids|synthetic cannabinoid]] that acts as a potent [[cannabinoid]] [[agonist]]. It is highly selective for the [[cannabinoid receptor type 2|cannabinoid-2 receptor]] (CB<sub>2</sub> receptor) subtype, with a selectivity more than 5,000 times greater for the CB<sub>2</sub> receptor than the [[CB1 receptor|CB<sub>1</sub> receptor]].<ref name="Mechoulam 1990">{{cite journal| vauthors = Mechoulam R, Lander N, Breuer A, Zahalka J |date=1990-04-11|title=Synthesis of the individual, pharmacologically distinct enantiomers of a tetrahydrocannabinol derivative|journal=Tetrahedron Asymmetry|volume=1|issue=5|language=en|pages=315–318|doi=10.1016/S0957-4166(00)86322-3|pmid=|pmc=|issn=|doi-access=free}}</ref><ref name="Hanus et al 1999">{{cite journal | vauthors = Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E | display-authors = 6 | title = HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 96 | issue = 25 | pages = 14228–14233 | date = December 1999 | pmid = 10588688 | pmc = 24419 | doi = 10.1073/pnas.96.25.14228 | doi-access = free | bibcode = 1999PNAS...9614228H }}</ref><ref>{{cite web |title=Properties of HU-308 ~ Formula C27H42O3 |url=http://pqr.pitt.edu/mol/CFMRIVODIXTERW-BHIFYINESA-N |website=Pitt Quantum Repository |publisher=University of Pittsburgh Department of Chemistry}}</ref> The [[chemical synthesis|synthesis]] and characterization of onternabez took place in the laboratory of [[Raphael Mechoulam]] at the [[Hebrew University of Jerusalem]] (the HU in HU-308) in the late 1990s. The [[pinene]] dimethoxy-DMH-CBD derivative onternabez was identified as a potent peripheral CB<sub>2</sub>-selective agonist in ''in vitro'' and animal studies in 1990<ref name="Mechoulam 1990" /> and 1999.<ref name="Hanus et al 1999" /> |
||
== |
==Legal status== |
||
Onternabez is non-psychoactive and not scheduled at the federal level in the United States.<ref>{{Cite web |url=http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm |title=21 CFR — Schedules of controlled substances §1308.11 Schedule I. |access-date=2014-12-17 |archive-date=2009-08-27 |archive-url=https://web.archive.org/web/20090827043725/http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm |url-status=dead }}</ref> It is a Schedule I [[controlled substance]] in the state of [[Florida]] making it illegal to buy, sell, or possess there.<ref>{{cite web | url = http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html | work = Florida Statutes | title = Chapter 893 - Drug abuse prevention and control }}</ref> |
|||
== See also == |
|||
* [[Cannabidiol dimethyl ether]] |
|||
* [[Cannabidiol diacetate]] |
|||
* [[HU-210]] |
* [[HU-210]] |
||
* [[HU-320]] |
* [[HU-320]] |
||
* [[HU-211]] |
|||
* [[Nabilone]] |
|||
* [[CP 47,497]] |
|||
==References== |
== References == |
||
{{reflist}} |
{{reflist}} |
||
{{Cannabinoids}} |
{{Cannabinoids}} |
||
[[Category: |
[[Category:Primary alcohols]] |
||
[[Category:Alcohols]] |
|||
[[Category:Phenol ethers]] |
[[Category:Phenol ethers]] |
||
[[Category:HU cannabinoids]] |
[[Category:HU cannabinoids]] |
||
[[Category:Designer drugs]] |
[[Category:Designer drugs]] |
||
[[Category:CB2 receptor |
[[Category:CB2 receptor agonists]] |
||
{{cannabinoid-stub}} |
Latest revision as of 08:24, 16 October 2024
Clinical data | |
---|---|
Other names | HU-308, HU308, PPP-003, ARDS-003 |
Drug class | CB2 receptor agonist |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Liver |
Excretion | Kidneys |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H42O3 |
Molar mass | 414.630 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Onternabez (also known as HU-308, HU308, PPP-003, and ARDS-003) is a synthetic cannabinoid that acts as a potent cannabinoid agonist. It is highly selective for the cannabinoid-2 receptor (CB2 receptor) subtype, with a selectivity more than 5,000 times greater for the CB2 receptor than the CB1 receptor.[1][2][3] The synthesis and characterization of onternabez took place in the laboratory of Raphael Mechoulam at the Hebrew University of Jerusalem (the HU in HU-308) in the late 1990s. The pinene dimethoxy-DMH-CBD derivative onternabez was identified as a potent peripheral CB2-selective agonist in in vitro and animal studies in 1990[1] and 1999.[2]
Legal status
[edit]Onternabez is non-psychoactive and not scheduled at the federal level in the United States.[4] It is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess there.[5]
See also
[edit]References
[edit]- ^ a b Mechoulam R, Lander N, Breuer A, Zahalka J (1990-04-11). "Synthesis of the individual, pharmacologically distinct enantiomers of a tetrahydrocannabinol derivative". Tetrahedron Asymmetry. 1 (5): 315–318. doi:10.1016/S0957-4166(00)86322-3.
- ^ a b Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. (December 1999). "HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor". Proceedings of the National Academy of Sciences of the United States of America. 96 (25): 14228–14233. Bibcode:1999PNAS...9614228H. doi:10.1073/pnas.96.25.14228. PMC 24419. PMID 10588688.
- ^ "Properties of HU-308 ~ Formula C27H42O3". Pitt Quantum Repository. University of Pittsburgh Department of Chemistry.
- ^ "21 CFR — Schedules of controlled substances §1308.11 Schedule I." Archived from the original on 2009-08-27. Retrieved 2014-12-17.
- ^ "Chapter 893 - Drug abuse prevention and control". Florida Statutes.